Progression-free survival on endocrine therapy, before or after chemotherapy, in hormone receptor-positive HER2-negative metastatic breast cancer

被引：0
作者：
Pauline Corbaux
Audrey Lardy-Cleaud
Marie Alexandre
Maxime Fontanilles
Christelle Lévy
Alessandro Adriano Viansone
Audrey Mailliez
Marc Debled
Anthony Goncalves
Fanny Le Du
Florence Lerebours
Jean-Marc Ferrero
Jean-Christophe Eymard
Marie-Ange Mouret-Reynier
Thierry Petit
Jean-Sébastien Frenel
Florence Dalenc
Coralie Courtinard
Marie Chaix
Thomas Bachelot
机构：
[1] Centre Léon Bérard,Department of Medical Oncology
[2] Centre Léon Bérard,Biostatistics Unit, DRCI
[3] Institut Régional du Cancer de Montpellier,Department of Medical Oncology
[4] Centre Henri Becquerel,Department of Medical Oncology
[5] Centre François Baclesse,Department of Medical Oncology
[6] Institut Gustave Roussy,Department of Cancer Medicine
[7] Centre Oscar Lambret,Department of Medical Oncology
[8] Institut Bergonié,Department of Medical Oncology
[9] Institut Paoli-Calmettes,Department of Medical Oncology
[10] Centre Eugène Marquis,Department of Medical Oncology
[11] Institut Curie,Department of Medical Oncology
[12] Centre Antoine Lacassagne,Department of Medical Oncology
[13] Institut Jean Godinot,Department of Medical Oncology
[14] Centre Jean Perrin,Department of Medical Oncology
[15] Centre Paul Strauss,Department of Medical Oncology
[16] Institut de Cancérologie de l’Ouest René Gauducheau,Department of Medical Oncology
[17] Institut Claudius Regaud—IUCT Oncopole,Department of Medical Oncology
[18] Unicancer,Data Office
[19] Université de Bordeaux,Inserm, Bordeaux Population Health Research Center, Epicene Team, UMR 1219
[20] Centre Hospitalier Universitaire Dijon Bourgogne,Department of Medical Oncology
来源：
Breast Cancer Research and Treatment | 2022年 / 191卷
关键词：
Advanced breast cancer; HR+/HER2−; Endocrine therapy; Chemotherapy; Progression-free survival; Real-word data;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：191 / 207
页数：16
相关论文
共 131 条
  • [1] Ghoncheh M(2016)Incidence and mortality and epidemiology of breast cancer in the world Asian Pac J Cancer Prev 17 43-46
  • [2] Pournamdar Z(2018)Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018 Eur J Cancer 1 356-387
  • [3] Salehiniya H(2014)US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status JNCI 137 1417-1426
  • [4] Ferlay J(2015)Twenty-years experience with de novo metastatic breast cancer Int J Cancer 2020 60-70
  • [5] Colombet M(1990)Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008–2016 Eur J Cancer Oxf Engl 29 1634-1657
  • [6] Soerjomataram I(2018)4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4) Ann Oncol 12 542-90
  • [7] Dyba T(2014)Breast cancer version 3.2014 J Natl Compr Cancer Netw 2021 CD002747-101
  • [8] Randi G(2003)Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer Cochrane Database Syst Rev 2018 93-120
  • [9] Bettio M(1990)Endocrine therapy or chemotherapy as first-line therapy in hormone receptor-positive HER2-negative metastatic breast cancer patients Eur J Cancer Oxf Engl 31 114-141
  • [10] Howlader N(2017)Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negative metastatic breast cancer: a propensity score analysis Breast Edinb Scotl 1990 131-262
12345678910